Evidence map›Paper›PMID 37755667›Full record

ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2023

Selective, broad-spectrum antiviral photodynamic disinfection with dicationic imidazolyl chlorin photosensitizers.

Zoe A Arnaut, Sara M A Pinto, Rafael T Aroso, Anita S Amorim, Catarina S Lobo, Fabio A Schaberle, Dina Pereira, Jisette Núñez, Sandra C C Nunes, Alberto A C C Pais and 4 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Zoe A ArnautChemistry Department, CQC-IMS, University of Coimbra, 3004-535, Coimbra, Portugal.
Sara M A PintoChemistry Department, CQC-IMS, University of Coimbra, 3004-535, Coimbra, Portugal.
Rafael T ArosoChemistry Department, CQC-IMS, University of Coimbra, 3004-535, Coimbra, Portugal.
Anita S AmorimChemistry Department, CQC-IMS, University of Coimbra, 3004-535, Coimbra, Portugal.
Catarina S LoboLaserLeap Technologies, R. Col. Júlio Veiga Simão, CTCV, Ed. B, 3025-307, Coimbra, Portugal.
Fabio A SchaberleChemistry Department, CQC-IMS, University of Coimbra, 3004-535, Coimbra, Portugal.
Dina PereiraCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, 3004-517, Coimbra, Portugal.
Jisette NúñezCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, 3004-517, Coimbra, Portugal.
Sandra C C NunesChemistry Department, CQC-IMS, University of Coimbra, 3004-535, Coimbra, Portugal.
Alberto A C C PaisChemistry Department, CQC-IMS, University of Coimbra, 3004-535, Coimbra, Portugal.
Paulo Rodrigues-SantosCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, 3004-517, Coimbra, Portugal.
Luis Pereira de AlmeidaCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, 3004-517, Coimbra, Portugal.
Mariette M PereiraChemistry Department, CQC-IMS, University of Coimbra, 3004-535, Coimbra, Portugal. mmpereira@qui.uc.pt.
Luis G ArnautChemistry Department, CQC-IMS, University of Coimbra, 3004-535, Coimbra, Portugal. lgarnaut@ci.uc.pt.ORCID http://orcid.org/0000-0002-3223-4819
University of Coimbra · PTLaserLeap Technologies (Portugal) · PT

Funding

Fundação para a Ciência e a Tecnologia ROTEIRO/0152/2013Fundação para a Ciência e a Tecnologia UID/QUI/00313/2019Fundação para a Ciência e Tecnologia FCT/BD/2021/09454Programa Operacional Regional do Centro CENTRO-01-0145-FEDER-181218
6 · The paper itself

Abstract

The COVID-19 pandemic exposes our vulnerability to viruses that acquire the ability to infect our cells. Classical disinfection methods are limited by toxicity. Existing medicines performed poorly against SARS-CoV-2 because of their specificity to targets in different organisms. We address the challenge of mitigating known and prospective viral infections with a new photosensitizer for antimicrobial photodynamic therapy (aPDT). Photodynamic inactivation is based on local oxidative stress, which is particularly damaging to enveloped viruses. We synthesized a cationic imidazolyl chlorin that reduced by > 99.999% of the percentage inhibition of amplification of SARS-CoV-2 collected from patients at 0.2 µM concentration and 4 J cm

Indexed as

Anti-Infective AgentsPhotochemotherapyAntiviral AgentsDisinfectionHEK293 CellsHumansPandemicsPhotosensitizing AgentsPorphyrinsProspective StudiesSARS-CoV-2Anti-Infective AgentsAntiviral AgentschlorinPhotosensitizing AgentsPorphyrinsChlorinsPhotodynamic inactivationPhotodynamic therapyPseudotyped lentiviral vectorReactive oxygen speciesSARS-CoV-2

Identifiers

PMID37755667
OpenAlexW4387077908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.